203792-32-9

Usage

Uses

Used in Pharmaceutical Research:
5-(AMINOMETHYL)FURAN-2-CARBONITRILE HYDROCHLORIDE is used as a potential drug candidate for the development of new therapeutic agents, particularly targeting neurological disorders and certain types of cancers. Its unique chemical structure allows it to be a promising candidate for the treatment of these conditions.
Used in Chemical Research:
In the realm of chemical research, 5-(AMINOMETHYL)FURAN-2-CARBONITRILE HYDROCHLORIDE serves as a building block for the synthesis of other organic compounds with diverse functionalities. Its presence in various chemical reactions can lead to the creation of new molecules with potential applications in different industries.
Used in Medicinal Chemistry:
5-(AMINOMETHYL)FURAN-2-CARBONITRILE HYDROCHLORIDE is used as a key intermediate in the synthesis of complex organic molecules with potential medicinal properties. Its ability to be modified and incorporated into larger structures makes it a valuable tool in the design and development of novel pharmaceuticals.
Used in Drug Discovery:
In the field of drug discovery, 5-(AMINOMETHYL)FURAN-2-CARBONITRILE HYDROCHLORIDE is utilized for its potential therapeutic applications. Researchers are exploring its properties to identify new ways to combat diseases and improve patient outcomes.
Used in Chemical Synthesis Industry:
5-(AMINOMETHYL)FURAN-2-CARBONITRILE HYDROCHLORIDE is used as a versatile intermediate in the synthesis of a wide range of organic compounds. Its reactivity and functional groups make it suitable for various chemical reactions, contributing to the development of new products in the chemical synthesis industry.

Upstream product

• 89149-70-2 5-hydroxymethyl-furan-2-carbonitrile 
• 148759-25-5 5-(bromomethyl)furan-2-carbonitrile 
• 42061-89-2 5-cyano-2-furancarboxaldehyde 
• 617-90-3 2-furancarbonitrile 
• 203792-31-8 C₁₆H₂₂N₂O₅ 

Relevant academic research and scientific papers

Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: Discovery of N-carboxymethyl-D-diphenylalanyl-L-prolyl[(5-amidino-2- thienyl)methyllamide

Thrombin, a crucial enzyme in the blood coagulation, has been a target for antithrombotic therapy. Orally active thrombin inhibitors would provide effective and safe prophylaxis for venous and arterial thrombosis. We conducted optimization of a highly efficacious benzamidine-based thrombin inhibitor LB30812 (3, Ki = 3 pM) to improve oral bioavailability. Of a variety of arylamidines investigated at the P1 position, 2,5-thienylamidine effectively replaced the benzamidine without compromising the thrombin inhibitory potency and oral absorption. The sulfamide and sulfonamide derivatization at the N-terminal position in general afforded highly potent thrombin inhibitors but with moderate oral absorption, while the well-absorbable N-carbamate derivatives exhibited limited metabolic stability in S9 fractions. The present work culminated in the discovery of the N-carboxymethyl- and 2,5-thienylamidine-containing compound 22 that exhibits the most favorable profiles of anticoagulant and antithrombotic activities as well as oral bioavilability (Ki = 15 pM; F = 43%, 42%, and 15% in rats, dogs, and monkeys, respectively). This compound on a gravimetric basis was shown to be more effective than a low molecular weight heparin, enoxaparin, in the venous thrombosis models of rat and rabbit. Compound 22 (LB30870) was therefore selected for further preclinical and clinical development.